Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity
Lilly(US:LLY) Seeking Alphaยท2025-09-21 12:44Company Overview - Eli Lilly (NYSE: LLY) is recognized as a leading player in the obesity and type 2 diabetes treatment markets, driven by the approvals of its drugs Zepbound and Mounjaro [2]. Market Opportunities - There are significant expansion opportunities for Eli Lilly in the obesity and type 2 diabetes treatment sectors, indicating potential for growth and increased market share [2].